Prestige Consumer Healthcare Inc. (PBH) Stock Analysis and Metrics

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001295947

Market Cap 2.80 Bn

P/E 15.36

P/S 2.54

Div. Yield 0.00

ROIC (Qtr) 0.10

Revenue Growth (1y) (Qtr) -2.37

Add ratio to table...

About

Prestige Consumer Healthcare Inc., or PBH, operates in the healthcare industry, specifically in the development, manufacturing, marketing, and distribution of over-the-counter (OTC) health and personal care products in North America and internationally. The company operates through two reportable segments: North American OTC Healthcare and International OTC Healthcare. PBH's primary business activities include the management of a diversified portfolio of well-recognized consumer brands, maintenance of strong market positions, and the implementation...

Prestige Consumer Healthcare Inc., or PBH, operates in the healthcare industry, specifically in the development, manufacturing, marketing, and distribution of over-the-counter (OTC) health and personal care products in North America and internationally. The company operates through two reportable segments: North American OTC Healthcare and International OTC Healthcare.

PBH's primary business activities include the management of a diversified portfolio of well-recognized consumer brands, maintenance of strong market positions, and the implementation of a low-cost operating model. The company's strategy for growth involves the development and introduction of new products, investment in advertising and marketing, expansion of distribution channels, pursuit of strategic acquisitions, and growth of its international business.

In terms of revenue generation, PBH's major brands, which include BC and Goody's Analgesics, Boudreaux's Butt Paste Dermatologicals, Chloraseptic Cough & Cold, Clear Eyes Eye & Ear Care, Compound W Dermatologicals, Debrox Eye & Ear Care, Dramamine Gastrointestinal, Fleet Gastrointestinal, Gaviscon Gastrointestinal, Luden's Cough & Cold, Monistat Women's Health, Nix Dermatologicals, and Summer's Eve Women's Health, account for a significant portion of the company's total revenues for the years 2024, 2023, and 2022. These brands cater to a wide range of health and personal care needs, such as analgesics, dermatologicals, cough and cold, eye and ear care, gastrointestinal, and women's health products. PBH's primary customers include Walmart and Amazon, which account for a significant portion of the company's sales.

PBH holds a strong position within the industry, characterized by its ability to acquire, integrate, and grow brands, as well as its history of growth through acquisitions. The company's competitive advantages include its diversified portfolio of well-recognized consumer brands, strong market positions, and low-cost operating model.

PBH's products are sold through multiple channels, including mass merchandisers, drug, food, dollar, convenience, club stores, and e-commerce channels. This reduces the company's exposure to any single distribution channel.

The following are the brand names and/or trade names of PBH's products: BC and Goody's Analgesics, Boudreaux's Butt Paste Dermatologicals, Chloraseptic Cough & Cold, Clear Eyes Eye & Ear Care, Compound W Dermatologicals, Debrox Eye & Ear Care, Dramamine Gastrointestinal, Fleet Gastrointestinal, Gaviscon Gastrointestinal, Luden's Cough & Cold, Monistat Women's Health, Nix Dermatologicals, and Summer's Eve Women's Health.

PBH operates under extensive regulation by various U.S. federal agencies, including the U.S. Food and Drug Administration (FDA), the Federal Trade Commission (FTC), the Consumer Product Safety Commission (CPSC), and the Environmental Protection Agency (EPA), as well as various agencies of the states, localities, and foreign countries in which its products are manufactured, marketed, distributed, and sold. The company is committed to providing a safe work environment for its employees and encourages them to become involved in their respective communities.

PBH's sales are impacted by consumer spending levels, the availability of its products at retail stores or for online purchase, and its ability to manufacture and distribute products to its customers and consumers in an effective and efficient manner. Additionally, the company faces risks associated with doing business internationally, political instability, declining economic conditions, and the oversight of various agencies of the states, localities, and foreign countries.

In recent years, there has been an increasing focus on Environmental, Social, and Governance (ESG) issues, including those related to climate change. PBH's failure to meet its customers' ESG expectations could result in a loss of customers, revenue, and reputation. Furthermore, the company is subject to risks related to intellectual property and data privacy and security.

Investment thesis

Bull case

Prestige’s pivot to in‑house production through the Pillar Five acquisition signals a long‑term supply chain resilience that the market has not fully priced in. The new high‑speed line is already operational and is expected to meet the majority of Clear Eyes volume, allowing the company to reduce reliance on third‑party mix‑and‑fill facilities that suffered recent disruptions. By internalizing production, Prestige can lower variable costs, better match inventory to demand signals, and gain the flexibility to expand the Clear Eyes SKU portfolio without the lead time currently limiting shelf replenishment. These capabilities position the company to capture the aging demographic’s sustained need for eye care products while mitigating the impact of future external supply shocks.
Despite a 2.4% quarterly revenue decline, the firm’s gross margin has risen to 55.5%, a 50‑basis‑point year‑over‑year increase that demonstrates operational discipline amid headwinds. The company’s effective cost‑control measures—including disciplined A&M spending and targeted G&A optimization—have preserved profitability. Higher margins translate into stronger free cash flow generation, which the firm is already deploying in disciplined share repurchases and potential future acquisitions. This healthy cash position enhances investor confidence and allows Prestige to navigate the current consumer volatility without compromising growth investments.
E‑commerce growth has surpassed 10% in the quarter, and the firm’s diversified channel mix means it can capture shifting consumer behavior regardless of where shoppers choose to purchase. The company’s ability to adapt marketing spend across digital and retail platforms, as highlighted by the CEO, underscores its operational agility. As e‑commerce continues to expand, the company’s brand portfolio—particularly GI and skin products—can leverage the growing online channel to accelerate top‑line momentum without significant additional cost. This e‑commerce upside is a catalyst that the market has not fully appreciated, especially given the firm’s historical resilience in other categories.
The firm’s strategic focus on high‑margin brands such as Fleet, Dramamine, and Monistat, combined with ongoing development in the women’s health and skin segments, indicates a diversified growth engine. The company’s long‑term growth algorithm projects 5% annual segment revenue growth, which, when combined with improving supply for Clear Eyes, could drive the forecasted $1.1 billion in FY‑2026 revenue. Management’s confidence that consumer demand will rebound as inventory constraints ease suggests that the company’s guidance may be conservative, leaving upside potential for investors.
The company’s capital allocation discipline, demonstrated by over $150 million in share repurchases year‑to‑date, highlights a management team that is focused on maximizing shareholder value. By maintaining a leverage ratio of 2.6× and generating $245 million or more in free cash flow for FY‑2026, Prestige is in a position to return capital to shareholders or pursue strategic acquisitions that can further strengthen its portfolio. The firm’s emphasis on disciplined capital deployment provides a cushion against potential downturns while simultaneously creating opportunities for value creation.

Prestige’s pivot to in‑house production through the Pillar Five acquisition signals a long‑term supply chain resilience that the market has not fully priced in. The new high‑speed line is already operational and is expected to meet the majority of Clear Eyes volume, allowing the company to reduce reliance on third‑party mix‑and‑fill facilities that suffered recent disruptions. By internalizing production, Prestige can lower variable costs, better match inventory to demand signals, and gain the flexibility to expand the Clear Eyes SKU portfolio without the lead time currently limiting shelf replenishment. These capabilities position the company to capture the aging demographic’s sustained need for eye care products while mitigating the impact of future external supply shocks.
Despite a 2.4% quarterly revenue decline, the firm’s gross margin has risen to 55.5%, a 50‑basis‑point year‑over‑year increase that demonstrates operational discipline amid headwinds. The company’s effective cost‑control measures—including disciplined A&M spending and targeted G&A optimization—have preserved profitability. Higher margins translate into stronger free cash flow generation, which the firm is already deploying in disciplined share repurchases and potential future acquisitions. This healthy cash position enhances investor confidence and allows Prestige to navigate the current consumer volatility without compromising growth investments.
E‑commerce growth has surpassed 10% in the quarter, and the firm’s diversified channel mix means it can capture shifting consumer behavior regardless of where shoppers choose to purchase. The company’s ability to adapt marketing spend across digital and retail platforms, as highlighted by the CEO, underscores its operational agility. As e‑commerce continues to expand, the company’s brand portfolio—particularly GI and skin products—can leverage the growing online channel to accelerate top‑line momentum without significant additional cost. This e‑commerce upside is a catalyst that the market has not fully appreciated, especially given the firm’s historical resilience in other categories.
The firm’s strategic focus on high‑margin brands such as Fleet, Dramamine, and Monistat, combined with ongoing development in the women’s health and skin segments, indicates a diversified growth engine. The company’s long‑term growth algorithm projects 5% annual segment revenue growth, which, when combined with improving supply for Clear Eyes, could drive the forecasted $1.1 billion in FY‑2026 revenue. Management’s confidence that consumer demand will rebound as inventory constraints ease suggests that the company’s guidance may be conservative, leaving upside potential for investors.
The company’s capital allocation discipline, demonstrated by over $150 million in share repurchases year‑to‑date, highlights a management team that is focused on maximizing shareholder value. By maintaining a leverage ratio of 2.6× and generating $245 million or more in free cash flow for FY‑2026, Prestige is in a position to return capital to shareholders or pursue strategic acquisitions that can further strengthen its portfolio. The firm’s emphasis on disciplined capital deployment provides a cushion against potential downturns while simultaneously creating opportunities for value creation.

Bear case

Clear Eyes remains a significant growth lever, yet the company acknowledges that supply constraints will persist through fiscal 2027, implying a multi‑quarter recovery that could strain short‑term revenue momentum. Management’s admission of ongoing destocking in retail channels and the need for sequential restocking suggests that consumer volatility is likely to continue affecting order patterns. If the supply chain issues persist, the company may face repeated quarterly revenue contractions, undermining investor confidence in its growth projections.
The $10 million write‑off of a supplier loan, while isolated, highlights exposure to counterparty risk that is difficult to quantify. Management’s statement that the asset recovery is “not estimable” introduces uncertainty into the company’s balance sheet. If additional supplier insolvencies arise, the company could be forced to absorb further write‑offs, eroding profitability and potentially requiring additional capital to maintain operations.
Management’s guidance for FY‑2026 revenue of approximately $1.1 billion reflects a cautious stance, with the company citing “slow order patterns” and “consumer volatility” as key limiting factors. The guidance remains at the lower end of the prior range, indicating that the company may be underestimating the magnitude of the headwinds. If the retail environment does not normalize as expected, the company may fall short of its sales targets, creating a downward pressure on stock price.
The firm’s reliance on channel diversity is a double‑edged sword. While it provides resilience, it also introduces complexity in inventory management and demand forecasting. The company’s own acknowledgment of “inventory destocking” and “volatile environment” indicates challenges in aligning supply with demand across multiple retail partners. Misalignment could result in overstock in some channels and stockouts in others, leading to lost sales and erosion of brand trust among consumers.
The company’s capital allocation strategy, while disciplined, involves significant share repurchases that consume a substantial portion of free cash flow. While share buybacks can boost earnings per share, they also reduce the buffer available for investing in growth initiatives, particularly in a period where supply chain issues and potential category softness may require additional capital. If the firm’s growth engine slows, the lack of available cash for strategic initiatives could become a constraint.

Clear Eyes remains a significant growth lever, yet the company acknowledges that supply constraints will persist through fiscal 2027, implying a multi‑quarter recovery that could strain short‑term revenue momentum. Management’s admission of ongoing destocking in retail channels and the need for sequential restocking suggests that consumer volatility is likely to continue affecting order patterns. If the supply chain issues persist, the company may face repeated quarterly revenue contractions, undermining investor confidence in its growth projections.
The $10 million write‑off of a supplier loan, while isolated, highlights exposure to counterparty risk that is difficult to quantify. Management’s statement that the asset recovery is “not estimable” introduces uncertainty into the company’s balance sheet. If additional supplier insolvencies arise, the company could be forced to absorb further write‑offs, eroding profitability and potentially requiring additional capital to maintain operations.
Management’s guidance for FY‑2026 revenue of approximately $1.1 billion reflects a cautious stance, with the company citing “slow order patterns” and “consumer volatility” as key limiting factors. The guidance remains at the lower end of the prior range, indicating that the company may be underestimating the magnitude of the headwinds. If the retail environment does not normalize as expected, the company may fall short of its sales targets, creating a downward pressure on stock price.
The firm’s reliance on channel diversity is a double‑edged sword. While it provides resilience, it also introduces complexity in inventory management and demand forecasting. The company’s own acknowledgment of “inventory destocking” and “volatile environment” indicates challenges in aligning supply with demand across multiple retail partners. Misalignment could result in overstock in some channels and stockouts in others, leading to lost sales and erosion of brand trust among consumers.
The company’s capital allocation strategy, while disciplined, involves significant share repurchases that consume a substantial portion of free cash flow. While share buybacks can boost earnings per share, they also reduce the buffer available for investing in growth initiatives, particularly in a period where supply chain issues and potential category softness may require additional capital. If the firm’s growth engine slows, the lack of available cash for strategic initiatives could become a constraint.

Segments Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TAK	Takeda Pharmaceutical Co Ltd	202.50 Bn	40.69	6.74	27.43 Bn
2	ZTS	Zoetis Inc.	51.58 Bn	19.29	5.45	9.04 Bn
3	TEVA	Teva Pharmaceutical Industries Ltd	32.45 Bn	22.85	1.88	16.81 Bn
4	UTHR	UNITED THERAPEUTICS Corp	26.06 Bn	19.51	8.19	-
5	ACB	Aurora Cannabis Inc	15.01 Bn	93.81	-2,482.90	0.04 Bn
6	NBIX	Neurocrine Biosciences Inc	12.80 Bn	26.69	4.47	-
7	HCM	HUTCHMED (China) Ltd	12.21 Bn	26.85	22.27	0.09 Bn
8	ELAN	Elanco Animal Health Inc	11.64 Bn	-49.87	2.47	4.02 Bn

Research Tools

Prestige Consumer Healthcare Inc. (NYSE: PBH)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Research Tools

Prestige Consumer Healthcare Inc. (NYSE: PBH)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password